The Yale Center for the Science of Cannabis and Cannabinoids, YC-SCAN², recently announced that it has awarded more than $600,000 in grants to 14 researchers from the Yale School of Medicine for innovative projects on the impact of cannabis and cannabinoids on neurodevelopment and mental health. These grants reflect YC-SCAN²'s ongoing commitment to advancing research in this rapidly evolving field.
Established in 2023, YC-SCAN² aims to be a leading hub for cannabis and cannabinoid science, conducting cutting-edge research while disseminating key findings to healthcare professionals and the public. Under the direction of Deepak Cyril D'Souza, MD, the center is focused on studying how cannabis affects the brain and overall health, particularly as legal markets continue to grow across the U.S.
"We received a highly competitive set of applications, making for a challenging selection process," said Dr. D'Souza. "The projects cover a broad range of topics, from the effects of cannabinoids on fetal and adolescent brain development, to the therapeutic potential of cannabinoids for pain and mental health disorders. We are optimistic that these projects will advance the science of cannabis and cannabinoids."
Key Research Areas
The awarded projects span a variety of important research topics, including the effects of cannabis on brain development and its therapeutic potential for mental health conditions. For example, Nicola Micali, PhD, will explore the impact of prenatal exposure to cannabinoids on primate brain development, which may shed light on similar effects in humans. Kristen Brennand, PhD, is studying how prenatal exposure to THC could increase the risk of psychiatric disorders later in life.
In pain management, Godfrey D. Pearlson, MD, is leading a study on the use of beta-caryophyllene, a cannabinoid, to treat chronic pain from reflex sympathetic dystrophy, a type of neuropathic pain. This project will investigate whether cannabinoids can offer an effective treatment for conditions that are typically resistant to traditional painkillers.
Cannabis And Mental Health
Many of the funded projects focus on the mental health implications of cannabis use, particularly its potential link to psychiatric conditions like schizophrenia and psychosis. Albert Powers, MD, PhD, and Jose Cortes-Briones, PhD, are investigating whether cannabis-induced brain states mimic the early stages of psychosis, providing crucial insights into cannabis's role in the development of mental health disorders.
Additionally, Mohini Ranganathan, MD, will evaluate the impact of cannabis use on schizophrenia risk using advanced neuroimaging techniques. This research will help clarify whether cannabis use increases the likelihood of developing psychotic disorders, especially in individuals with a genetic predisposition.
Looking To The Future Of Cannabis Research
YC-SCAN²'s commitment to funding this diverse research reflects the growing need for rigorous scientific studies into the effects of cannabis. Dr. D'Souza expressed confidence that these studies will contribute to a deeper understanding of cannabis and its potential therapeutic uses. “These projects are led by investigators at different stages of their careers and employ several novel approaches. We are hopeful that these studies will bring Yale to the forefront of cannabis research.”
The projects funded by YC-SCAN² will not only contribute to the scientific community but will also help educate healthcare professionals and the public about the complex role cannabis plays in human health. The research findings will be shared widely, with the goal of shaping both policy and medical practices related to cannabis use.
Cover image made with AI
